| 1 |
29375004 | Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes. | 2019 Feb |
1 |
| 2 |
22842957 | Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. | 2013 Mar |
4 |
| 3 |
20609060 | Inhibition of human liver microsomal CYP by nateglinide. | 2010 May |
4 |
| 4 |
20809476 | Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. | 2010 Nov |
2 |
| 5 |
17253883 | Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. | 2007 |
1 |
| 6 |
18159128 | Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. | 2007 Dec |
2 |
| 7 |
16042675 | Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. | 2005 Aug |
1 |
| 8 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
2 |
| 9 |
14741071 | The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. | 2004 Jan |
1 |
| 10 |
14748619 | Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. | 2004 |
1 |
| 11 |
15005635 | Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. | 2004 |
7 |
| 12 |
15197517 | Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. | 2004 Aug |
5 |